Jane Street’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Jane Street’s Portfolio GNMX Stock Details GNMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-12,102	Closed	-$8K	–	5979
2018 Q4	$8K	Buy	+12,102	New	+$13.5K	﹤0.01%	4833

Other funds holding GNMX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jane Street's GNMX Position: Q1 2019 in Review

Jane Street sold out of Aevi Genomic Medicine Inc (GNMX) in Q1 2019, closing a stake of 12,102 shares — an estimated $8K sold.

Jane Street first reported a position in GNMX in Q4 2018 and held it in 1 quarter. The position peaked at $8K in Q4 2018. 28 funds tracked by Wall St. Rank hold GNMX as of Q1 2019.

Jane Street reported no remaining Aevi Genomic Medicine Inc position as of Q1 2019 after selling out during the quarter.
Jane Street sold 12,102 Aevi Genomic Medicine Inc shares in Q1 2019, an estimated $8K.
Jane Street first reported a position in Aevi Genomic Medicine Inc in Q4 2018 and held it in 1 quarter.
Jane Street's Aevi Genomic Medicine Inc position peaked at $8K in Q4 2018.
28 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q1 2019.

Based on Jane Street's 13F filing for Q1 2019, filed 16 May 2019.